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Abstract Axonal damage leads to permanent deficits in the
adult central nervous system (CNS) not only because of the
weak intrinsic ability of adult neurons to activate their
growth program but importantly also because of the pres-
ence of specific growth inhibitors in the CNS tissue and the
environment of the damaged axons. The well-studied
myelin-derived protein Nogo-A is involved in various cel-
lular and molecular events contributing to the failure of CNS
axons to regrow and reconnect after transection. Recent
studies have shown that, by acting in a negative way on
the cytoskeleton and on the growth program of axotomized
neurons, Nogo-A exerts fast and chronic inhibitory effects
on neurite outgrowth. On the other hand, the blockade of
Nogo-A results in a marked enhancement of compensatory
and regenerative axonal extension in vivo; this enhancement
is often paralleled by significant functional recovery, for
example, of locomotion or skilled forelimb reaching after
spinal cord or stroke lesions in rats and monkeys. Surpris-
ingly, the blockade of Nogo-A or its receptor NgR in the
hippocampus has recently been demonstrated to enhance long-
term potentiation. A role of Nogo-A in synaptic plasticity/
stability might therefore represent an additional, new and
important aspect of CNS circuit remodeling. Function-
blocking anti-Nogo-A antibodies are currently being tested
in a clinical trial for improved outcome after spinal cord
injury.
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Nogo-A protein expression in the intact and injured
central nervous system
Nogo-A is a transmembrane protein of about 1200 amino acids
(aa) including a C-terminal 200-aa reticulon (RTN) domain
(Chen et al. 2000; GrandPre et al. 2000). It has been purified
from mammalian central nervous system (CNS) myelin and is
one of themost potent neurite growth inhibitors in CNSmyelin
and tissue (Spillmann et al. 1998). Nogo-A is mainly expressed
by oligodendrocytes in the adult CNS (Huber et al. 2002;
Wang et al. 2002b). The high endogenous expression of
Nogo-A by oligodendrocytes shows little increase around a
spinal cord injury site (Huber et al. 2002). Before myelin
formation, Nogo-A is strongly expressed by developing and
immature neurons and neuronal Nogo-A persists at a high level
in plastic CNS regions such as the cortex, the hippocampus and
dorsal root ganglia (Huber et al. 2002; Peng et al. 2011). The
presence of Nogo-A in plastic areas of the adult CNS appears
paradoxical and suggests additional functions unrelated to
axonal plasticity. Nevertheless, after axonal severing in the
optic nerve, we have observed an up-regulation of Nogo-A
that is most striking in a subpopulation of retinal ganglion cells
with larger soma sizes (Pernet et al. 2011). In the pyramidal
neurons and interneurons of the cortex, increased Nogo-A
levels have been seen in stroke perilesional areas (Cheatwood
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et al. 2008). The functions of Nogo-A under these conditions
of neuronal damage are not known.
Nogo-A neutralization or knock-out or Nogo receptor
suppression enhances axonal growth after injury
The functional deficits after spinal cord injury depend on the
location and severity of the damage. In the case of an
incomplete spinal cord lesion, a spontaneous remodeling
of intraspinal circuits, e.g., by the formation of detour path-
ways, contributes to the recovery of hindlimb function
(Bareyre et al. 2004). Under more severe lesion conditions
in which recovery is not observed, the intrathecal infusion of
function-blocking anti-Nogo-A antibodies significantly
improves sensory-motor functions and stimulates axonal
sprouting from damaged and intact fibers (Thallmair et al.
1998; Raineteau et al. 2001; Liebscher et al. 2005; Freund et
al. 2006, 2009; Gonzenbach et al. 2012). Long-range axonal
regeneration and increased compensatory growth of intact
fibers have been observed after the application of various anti-
Nogo-A antibodies. A delay in the delivery of these antibodies
by 1 week but not 2 weeks, is efficient to increase cortico-
spinal tract axon regeneration over several millimeters after
dorsal thoracic spinal cord lesion (Gonzenbach and Schwab
2008). Consistent with this, hindlimb function is improved
when antibody infusion begins no later than 1 week after
injury. In contrast, in a rat stroke model, skilled forelimb
movements recover, even when anti-Nogo-A treatment is
started as late as 9 weeks after ischemic brain damage (Tsai
et al. 2011). Importantly, similar anatomical and behavioral
results have been obtained with reagents blocking the Nogo
receptor NgR1 (Li and Strittmatter 2003; Lee et al. 2004;
Wang et al. 2006, 2011), the NgR-associated protein Lingo-1
(Ji et al. 2006), or the downstream signaling components RhoA
(Dergham et al. 2002; Fournier et al. 2003; Lord-Fontaine et al.
2008) or ROCK (Fournier et al. 2003; Duffy et al. 2009). All
these findings not only establish a strong proof-of-principle for
the clinical use of Nogo-A immunotherapy in different CNS
injury types but also raise interesting questions about the
normal physiological role played by Nogo-A in the complex
CNS of higher vertebrates.
Function-blocking antibodies directed against Nogo-A
have been extensively used by our group and have allowed
us to develop a potential therapy to treat human CNS injuries
and diseases. In vivo experiments in rats and in monkeys
represent essential preclinical tests to validate the efficiency
and safety of Nogo-A antibody administration. In non-human
primates, the dexterity of the paralyzed arm and hand after a
cervical hemisection is almost completely restored by the
intrathecal delivery of a Nogo-A-specific antibody (Freund
et al. 2006, 2009). Fine motor movement recovery is associ-
ated with a large amount of corticospinal axon sprouting past
the lesion site and innervation of the lower cervical cord
segments. The concept of therapeutic antibody administration
in the CNS was first tested in clinical trials targeting Nogo-A;
the anti-human Nogo-A antibody ATI355 produced in collab-
oration with Novartis Pharma (Basel) has recently been estab-
lished as being safe for patients with spinal cord injuries in a
Phase I clinical trial (http://clinicaltrials.gov/ct2/show/
NCT00406016) with 52 acutely injured, severe para- and
tetraplegic patients (Abel et al. 2011). A placebo-controlled
Phase II clinical trial is currently in preparation. In another
CNS disease, amyotrophic lateral sclerosis (ALS), the ectopic
expression of Nogo-A at the neuromuscular junction is an
early sign of the disease and is thought to cause synapse
destabilization and thereby motor control loss (Dupuis et al.
2002; Jokic et al. 2005, 2006). As has been proposed for
spinal cord injury, GlaxoSmithKline (GSK) has developed a
humanized anti-Nogo-A antibody (GSK1223249) to prevent
Nogo-A-induced synaptic destabilization and motoneuron
degeneration in ALS (http://clinicaltrials.gov/ct2/show/
NCT00875446). Preliminary results of a Phase I clinical
trial have recently been presented (Pradat et al. 2011).
Intravenous injections of GSK1223249 appear to be well
tolerated by the 76 patients enrolled in the trial. A larger
Phase II international trial is scheduled for 2012 to assess the
therapeutic benefits of GSK1223249 on ALS symptoms.
Molecular mechanisms mediating Nogo-A-induced
axonal growth inhibition
Cell surface Nogo-A
Cytoskeleton regulation
Two principal domains of Nogo-A have been shown to exert
inhibitory effects on neurite outgrowth: the Nogo-66 sequence
in the C-terminal RTN region and a 160-aa fragment called
Nogo-A delta20 in the Nogo-A-specific region (Oertle et al.
2003b). A clear mechanism has been elucidated for Nogo-66-
mediated growth inhibition; a receptor complex composed of
the Nogo-66 receptor NgR1, a glycosyl-phosphatidylinositol-
linked leucine-rich repeat protein (Fournier et al. 2001) and
the NgR1-associated proteins Lingo (Mi et al. 2004) and p75
(Wang et al. 2002a) or Troy (Shao et al. 2005) is stimulated by
Nogo-66 leading to the intracellular activation of the RhoA/
ROCK/cofilin pathway that prevents actin cytoskeleton poly-
merization in the growth cone and thereby blocks neurite
extension (Nash et al. 2009; Fig. 1). Consistent with this, in
Nogo-A knock-out (KO) mice, growth cone motility is
increased compared with wild-types (Montani et al. 2009).
Surprisingly, the same receptor complex and downstream
mechanisms seem also to be involved in the growth inhib-
itory effects of other myelin-associated proteins, such as
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myelin-associated glycoprotein (MAG) and oligodendro-
cyte myelin glycoprotein (OMgp) (Wang et al. 2002a). One
way in which myelin-associated inhibitors activate the small
GTPase RhoA might be by the phosphorylation and inactiva-
tion of GSK3beta, thereby allowing CRMP4 and RhoA inter-
action (Alabed et al. 2010).
Another receptor has recently been identified for Nogo-66,
MAG and OMgp, called paired immunoglobulin-like
receptor-B (PirB; Atwal et al. 2008). In primary neuron cul-
tures, the blocking of PirB partially relieves the myelin-
protein-induced inhibition of axonal outgrowth (Atwal et al.
2008). However, the genetic deletion of PirB alone fails to
increase axonal growth in vivo after corticospinal tract tran-
section (Nakamura et al. 2011), traumatic brain lesion (Omoto
et al. 2010), or optic nerve crush (Fujita et al. 2011). As for
NgR1, the regenerative and behavioral outcomes observed
after PirB ablation might depend on the lesioned tract
(Cafferty and Strittmatter 2006) or on (yet unknown) co-
receptors. More work will be necessary to specify the contri-
bution of PirB to the molecular mechanisms underlying axo-
nal regeneration failure in vivo.
The biochemical mechanisms triggered by the Nogo-A
domain Nogo delta20 in neurons remain more elusive. The
receptor(s) bound by Nogo delta20 has(have) not been identi-
fied as yet. However, purified Nogo delta20 has been shown to
destabilize the cytoskeleton, as has been found for Nogo-66, in
a RhoA-dependent manner (Niederost et al. 2002; Joset et al.
2010).
Fig. 1 Molecular mechanisms of Nogo-A-mediated axonal growth
inhibition. a Organization of the growth cone. The growth cone is
composed of a central domain containing the microtubules involved in
the transport of organelles and of a peripheral domain in which actin
filaments (F-actin) form a cytoskeleton meshwork in the lamellipodia
and filopodia. The protrusion of the filopodia occurs at the plus end (+)
of the actin filament and is required to allow the traction of the growth
cone on the extracellular matrix. b Growth cone inhibition. The contact
of filopodial extensions with myelin-associated inhibitors such as
Nogo-A (1) triggers the quick collapse of F-actin in the growth cone
(2). The retrograde signaling is thought to mediate the long-term
effects of Nogo-A on the repression of the neuronal growth program
(3). c Nogo-66 and other myelin inhibitors exhibited at the cell surface
of oligodendrocytes bind to and stimulate a common neuronal receptor
complex. The transduction of the signal passes through the intracellular
activation of the RhoA/ROCK pathway and involves the actin-severing
enzyme cofilin, a main effector in the disassembly of the growth cone
cytoskeleton. Alternatively, the Nogo-A delta20 region is internalized
by an unknown receptor via a pincher-dependent mechanism. The
uptake of Nogo-A delta20 leads to the activation of the RhoA/
ROCK/cofilin cascade. In addition, the resulting molecular complex
can also be retrogradely transported in signalosomes to the neuronal cell
body in which it activates RhoA, negatively regulates phospho-CREB
and thereby attenuates the neuronal growth program (abbreviations are
explained in the text)
Cell Tissue Res (2012) 349:97–104 99
The neuronal growth program
The long-term effects of growth-promoting and growth-
repressing molecules are often regulated at the gene expres-
sion level. Our group has recently demonstrated that growth
cone collapse and RhoA activation require the Pincher-
dependent internalization of Nogo-A delta20 in primary
neurons. In addition to affecting the growth cone cytoskel-
eton assembly, Nogo-A-delta20-containing signalosomes
are retrogradely transported to the cell body in which they
activate RhoA, downregulate cAMP response element-
binding protein (CREB) phosphorylation and repress the
cellular growth program (Joset et al. 2010) (Fig. 1). Inter-
estingly, a similar mechanism of retrograde signaling has
previously been described for neurotrophic factors that exert
opposite growth-promoting effects on axons and that acti-
vate neuronal plasticity (Shao et al. 2002). Strikingly, the
group of Filbin has reported that neurotrophic factors can
overcome myelin-associated protein-mediated growth inhi-
bition by up-regulating cAMP and P-CREB, leading to the
activation of arginaseI expression, a rate-limiting enzyme
for the synthesis of polyamines (Cai et al. 2002; Gao et al.
2004). The signaling of negative and positive regulators of
axonal growth might therefore converge on the same intra-
cellular transcription factors. However, additional molecules
controlling the cellular growth program might be changed
after Nogo-A action, such as the signal transducer and
activator of transcription (Stat; Bareyre et al. 2002) or the
Akt (protein kinase B)-mTOR (mammalian target of rapa-
mycin) pathway. Recent observations suggest that Nogo-A
decreases synaptic protein translation by antagonizing
the mTOR activation required in long-term potentiation
(LTP; Baldwin et al. 2011). The role of those molecules
and pathways remains to be clarified in the CNS (Bareyre
et al. 2011).
At first glance, the presence of two inhibitory active sites
within the Nogo-A sequence seems intriguing. However,
interaction of more than one active site of a signaling
molecule with more than one subunit of a multi-subunit
receptor complex is well known, e.g., for neurotrophic
factors, Wnt, semaphorins, or netrin (Schwab 2010). The
two domains of Nogo-A might differ such that they mediate
plasticity and growth repression. For Nogo-A delta20, short-
and long-term inhibitory mechanisms might operate at the
cytoskeleton and gene expression level, whereas Nogo-66/
NgR1 has been proposed to induce acute growth cone
collapse and neurite growth inhibition but not chronic
outgrowth blockade (Chivatakarn et al. 2007). A bimod-
al functioning of Nogo-A via its two domains activating
distinct receptors or subunits might therefore contribute
to the acute and chronic impairment of axonal plasticity. This
could have relevance for the design of repair strategies for the
lesioned CNS.
Intracellular and endoplasmic-reticulum-associated Nogo-A
Role in survival and axonal regeneration
On the basis of its 200-aa C-terminus, Nogo-A belongs to
the RTN protein family, which is composed of four mem-
bers (RTN1, RTN2, RTN3, RTN4) present in eukaryotes
(Oertle et al. 2003a). Some structural and enzyme regulatory
functions have been described for RTNs; they can influence
the curvature of the endoplasmic reticulum (ER) and appear
as structural regulators for the subcompartment “tubular
ER” (Voeltz et al. 2006). RTNs can also interact with the
anti-apoptotic intracellular proteins Bcl-2 or Bcl-XL and
have therefore been claimed to play a role in cell death
regulation (Tagami et al. 2000; Wan et al. 2007).
In ischemia and after oxidative stress, Nogo-Amight act as a
neuroprotective molecule. After middle cerebral artery occlu-
sion, Nogo-A KO or the acute but not the delayed blockade of
Nogo-A with antibodies decreases neuronal survival (Kilic et
al. 2010). More recently, Nogo-A delta20 transfection in corti-
cal neurons has been shown to protect against hydrogen-
peroxide-induced cell death in vitro, supposedly by interacting
with the enzyme peroxiredoxin 2, which scavenges reactive
oxygen species (Mi et al. 2012).
Nogo-A has been observed to increase in the cell body of
injured neurons suggesting that it exerts cell-autonomous
effects on cell death and/or growth mechanisms (Cheatwood
et al. 2008; Pernet et al. 2011). ER stress is thought to play a
role in many degenerative diseases such as ALS (Atkin et al.
2006; Saxena et al. 2009), Alzheimer’s disease, or Parkinson’s
disease (Doyle et al. 2011). As an RTN protein, the expression
of which can change in compromised neurons, Nogo-A is
suspected of influencing ER stress activation. After optic
nerve injury, we have observed that Nogo-A is up-regulated
in neurons together with other ER-stress-associated markers
such as the pro-apoptotic transcription factor CHOP (Pernet et
al. 2011). However, we have been unable to detect a change in
CHOP expression or in the frequency of apoptosis when
injury-induced Nogo-A is silenced selectively in neurons or
fully deleted genetically. Our results are consistent with pre-
vious in vitro data showing that Nogo-A over-expression does
not enhance the level of CHOP or that of the chaperon protein
Bip (Yang et al. 2009). Therefore, the axon lesion-induced up-
regulation of Nogo-A in neurons does not seem to be an
important regulator of apoptosis in vivo.
Interaction of neuronal Nogo-A with β-secretase (BACE1)
The production of β-amyloid deposits is a hallmark of
Alzheimer’s disease. Interestingly, the group of Yan has
found in vitro that all RTN members including Nogo are
able to bind and to inhibit the β-amyloid-converting enzyme
1 (BACE1), which transforms the amyloid precursor protein
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(APP) into aggregating β-amyloid (He et al. 2004). In vivo,
however, the physiological role of RTNs in this context is
less clear. The over-expression of RTN3 in transgenic mice
reduces the production of β-amyloid in the hippocampus
but concomitantly causes the formation of RTN3 aggregates
in dystrophic neurites (Shi et al. 2009b). The excess of RTN
might compete with APP to bind BACE1, thereby seques-
tering BACE1 in the ER and prevent its enzymatic activity
on APP (Shi et al. 2009b). However, we do not know
whether RTNs and in particular Nogo-A, serve as substrates
for BACE1 and can be secreted, for example, as bioactive
fragments into the extracellular space. In addition, the
experimental over-expression of RTN3 might not faithfully
reproduce pathophysiological conditions such as those
encountered in aging brains (Shi et al. 2009a). Much remains
to be learnt at present on the possible roles of Nogo and RTN
proteins in the regulation of intracellular enzymes such as
BACE1 or of processes such as ER function or cell survival.
The re-formation of functional circuits after traumatic
CNS lesions
Function-blocking antibodies against Nogo-A, NgR1-blocking
peptides, antibodies against Lingo-1, or pharmacological
blockers of the signal transducers RhoA and ROCK have been
applied in various laboratories in spinal cord injury and stroke
models in rats, in mice and, in some instances, also in
monkeys. Enhancement of behavioral recovery in a variety
of sensory-motor tests and enhanced sprouting and long-
distance regeneration of lesioned and spared axons have
been found (Zorner and Schwab 2010). Importantly, a high
degree of similarity is present despite using different ways
to interrupt Nogo-A signaling. Similar but overall weaker
and variable results have been obtained in Nogo KO mice
in spinal cord injury studies (Kim et al. 2003; Simonen et al.
2003; Zheng et al. 2003; Dimou et al. 2006; Cafferty et al.
2010; Lee et al. 2010).
A defined succession of events probably controls the
formation of functional reconnections in the damaged brain
and spinal cord. A time window (1 week in the rat) seems to
exist during which Nogo-A immunotherapy is efficient at
activating spinal cord axon regeneration (Gonzenbach et al.
2012); the treatment with Nogo-A antibody has only weak
behavioral and anatomical effects when delayed by 2 weeks
after the injury compared with the acute or 1-week-delayed
administration. The neuronal growth response occurring
spontaneously after an axonal injury might condition the
effects of Nogo-A neutralization on axonal regrowth. In
the visual system, an intervention window has been defined
in the growth-promoting inflammation paradigm; intra-
ocular inflammation can only elicit axonal regeneration
when the treatment is delivered 3 days before or after optic
nerve crush injury but not after 7 days (Yin et al. 2003). The
time-course of growth-associated-molecule expression has
revealed that, soon after axon transection, neurons attempt
but fail to regenerate. Thus, the neutralization of Nogo-A
might also facilitate the growth of neurons early after injury.
The mechanisms of guidance of regenerating axons in the
adult CNS and the molecular determinants of target recog-
nition have not been studied so far. We do not know whether
sprouts and regenerating axons reconnect to their original
targets in the spinal cord or brain, or whether synapse
formation occurs randomly. Finally, mechanisms of stabili-
zation and pruning of connections and synapses, probably
driven by activity and use, might lead to the formation of
new functional circuits.
Nogo-A is a negative regulator of synaptic plasticity
The expression of Nogo-A in neurons or in glial cells might
also control the formation and stability of synaptic contacts
after a lesion. Most of our knowledge on the effects of Nogo-A
on synaptogenesis and synaptic transmission is derived from a
few developmental studies and from electrophysiological
investigations in the hippocampus. By contrast, little is known
as to the way in which Nogo-A blockade promotes functional
synapses in the adult damaged CNS. Oligodendrocyte-
expressed Nogo-A also acts as a growth-restricting factor in
the developing brain; in the visual cortex, the end of the
activity-driven plastic phase of synapse sprouting, pruning
and stabilization (“critical period”) coincides with the myeli-
nation of layers IV-VI and the expression of Nogo-A. Nogo
restricts the plasticity of the ocular dominance columns in the
adult visual cortex in an NgR1-dependent manner, as shown
by Nogo-KO and NgR1-KO mice analyses. Nogo/NgR1 sig-
naling might therefore be a contributor to the end of the plastic
so-called “critical period” (McGee et al. 2005).
In the adult hippocampus in which synaptic plasticity
remains elevated throughout life, Nogo-A is highly expressed
in pre- and postsynaptic neurons including CA3 and CA1
pyramidal cells (Lee et al. 2008). The addition of function-
blocking anti-Nogo-A antibodies or Nogo-A KO induces
marked changes in the complexity of the basal and apical
dendritic arbors of CA1 and CA3 neurons and leads to massive
sprouting of the CA3 axons (Zagrebelsky et al. 2010). The
proportion of immature spines is also higher in the CA3
neurons. The dendritic and spine phenotypes can be repro-
duced by silencing NgR1 expression. Nogo-A thus appears
here again as a stabilizer of synapses, the suppression of which
leads to growth and higher plasticity in axons and dendrites.
Electrophysiological recordings in acute hippocampal slices
have revealed that the inactivation of Nogo-A or NgR1 with
function-blocking antibodies or KOs increases LTP (Raiker et
al. 2010; Delekate et al. 2011). Whether both neuronal and
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glial Nogo-A influence synapse remodeling and LTP is not
known.
Concluding remarks
Nogo-A appears to be a major inhibitor of axonal regeneration;
it induces the quick destabilization of the actin cytoskeleton
and, on a longer time scale, represses growth gene expression.
Many studies have reported that the neutralization of Nogo-A
or Nogo-A receptor elements restores plasticity, improves
axonal growth and enhances behavioral recovery after injury
with no obvious side-effects. The high significance of these
results has prompted to test the effects of function-blocking
Nogo-A antibodies in patients with spinal cord injuries. Clin-
ical trials are currently ongoing. In contrast, the physiological
role of Nogo-A has been less-well studied. In the intact CNS,
Nogo-A might contribute to stabilizing axonal connectivity
(Park et al. 2010; Schwab 2010). Compelling evidence indi-
cates that Nogo-A also modulates synaptic contacts and neg-
atively influences LTP in the hippocampus. Thus, the
physiological function of Nogo-A in the healthy brain might
be to prevent abnormal sprouting and to regulate the dynamics
of the synaptic cytoskeleton during learning processes. Future
research will help us to understand the way that neuronal and
glial Nogo-A regulates nerve fiber growth and connectivity
and the fine tuning of synaptic plasticity in the developing and
adult CNS.
References
Abel R, Baron H-C, Casha S, Harms J, Hurlbert J, Kucher K, Maier D,
Thietje R, Weidner N, Curt A (2011) Therapeutic anti-Nogo-A
antibodies in acute spinal cord injury: safety and pharmacokinetic
data from an ongoing first-in-human trial. In: The International
Spinal Cord Society (ISCoS) (eds) International Conference on
Spinal Cord Medicine and Rehabilitation. Washington, D.C.,
USA, p 16
Alabed YZ, Pool M, Ong Tone S, Sutherland C, Fournier AE (2010)
GSK3 beta regulates myelin-dependent axon outgrowth inhibition
through CRMP4. J Neurosci 30:5635–5643
Atkin JD, FargMA, Turner BJ, TomasD, Lysaght JA, Nunan J, Rembach
A, Nagley P, Beart PM, Cheema SS, HorneMK (2006) Induction of
the unfolded protein response in familial amyotrophic lateral scle-
rosis and association of protein-disulfide isomerase with superoxide
dismutase 1. J Biol Chem 281:30152–30165
Atwal JK, Pinkston-Gosse J, Syken J, Stawicki S, Wu Y, Shatz C,
Tessier-Lavigne M (2008) PirB is a functional receptor for myelin
inhibitors of axonal regeneration. Science 322:967–970
Baldwin KT, Raiker S, Giger RJ (2011) Nogo-A negatively regulates mTor
signaling to inhibit synaptic function. In: Society For Neuroscience
(eds) Neuroscience 2011. Society For Neuroscience, Washington,
p 216.04
Bareyre FM, Haudenschild B, Schwab ME (2002) Long-lasting
sprouting and gene expression changes induced by the monoclonal
antibody IN-1 in the adult spinal cord. J Neurosci 22:7097–
7110
Bareyre FM,KerschensteinerM,RaineteauO,Mettenleiter TC,Weinmann
O, SchwabME (2004) The injured spinal cord spontaneously forms a
new intraspinal circuit in adult rats. Nat Neurosci 7:269–277
Bareyre FM, Garzorz N, Lang C, Misgeld T, Buning H, Kerschensteiner
M (2011) In vivo imaging reveals a phase-specific role of STAT3
during central and peripheral nervous system axon regeneration.
Proc Natl Acad Sci USA 108:6282–6287
Cafferty WB, Strittmatter SM (2006) The Nogo-Nogo receptor pathway
limits a spectrum of adult CNS axonal growth. J Neurosci 26:12242–
12250
Cafferty WB, Duffy P, Huebner E, Strittmatter SM (2010) MAG and
OMgp synergize with Nogo-A to restrict axonal growth and
neurological recovery after spinal cord trauma. J Neurosci 30:6825–
6837
Cai D, Deng K, Mellado W, Lee J, Ratan RR, Filbin MT (2002)
Arginase I and polyamines act downstream from cyclic AMP in
overcoming inhibition of axonal growth MAG and myelin in
vitro. Neuron 35:711–719
Cheatwood JL, Emerick AJ, Schwab ME, Kartje GL (2008) Nogo-A
expression after focal ischemic stroke in the adult rat. Stroke
39:2091–2098
Chen MS, Huber AB, Haar ME van der, Frank M, Schnell L, Spillmann
AA, Christ F, Schwab ME (2000) Nogo-A is a myelin-associated
neurite outgrowth inhibitor and an antigen for monoclonal antibody
IN-1. Nature 403:434–439
Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ (2007)
The Nogo-66 receptor NgR1 is required only for the acute growth
cone-collapsing but not the chronic growth-inhibitory actions of
myelin inhibitors. J Neurosci 27:7117–7124
Delekate A, Zagrebelsky M, Kramer S, Schwab ME, Korte M (2011)
NogoA restricts synaptic plasticity in the adult hippocampus on a
fast time scale. Proc Natl Acad Sci USA 108:2569–2574
Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD,
McKerracher L (2002) Rho signaling pathway targeted to promote
spinal cord repair. J Neurosci 22:6570–6577
Dimou L, Schnell L, Montani L, Duncan C, Simonen M, Schneider R,
Liebscher T, Gullo M, Schwab ME (2006) Nogo-A-deficient mice
reveal strain-dependent differences in axonal regeneration. J
Neurosci 26:5591–5603
Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A
(2011) Unfolded proteins and endoplasmic reticulum stress in
neurodegenerative disorders. J Cell Mol Med 15:2025–2039
Duffy P, SchmandkeA, Sigworth J, Narumiya S, CaffertyWB, Strittmatter
SM (2009) Rho-associated kinase II (ROCKII) limits axonal growth
after trauma within the adult mouse spinal cord. J Neurosci
29:15266–15276
Dupuis L, Gonzalez de Aguilar JL, Scala F di, Rene F, Tapia M de,
Pradat PF, Lacomblez L, Seihlan D, Prinjha R, Walsh FS,
Meininger V, Loeffler JP (2002) Nogo provides a molecular
marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis
10:358–365
Fournier AE, GrandPre T, Strittmatter SM (2001) Identification of a
receptor mediating Nogo-66 inhibition of axonal regeneration.
Nature 409:341–346
Fournier AE, Takizawa BT, Strittmatter SM (2003) Rho kinase inhibition
enhances axonal regeneration in the injured CNS. J Neurosci
23:1416–1423
Freund P, Schmidlin E, Wannier T, Bloch J, Mir A, Schwab ME,
Rouiller EM (2006) Nogo-A-specific antibody treatment enhan-
ces sprouting and functional recovery after cervical lesion in adult
primates. Nat Med 12:790–792
Freund P, Schmidlin E, Wannier T, Bloch J, Mir A, Schwab ME,
Rouiller EM (2009a) Anti-Nogo-A antibody treatment promotes
recovery of manual dexterity after unilateral cervical lesion in
adult primates—re-examination and extension of behavioral data.
Eur J Neurosci 29:983–996
102 Cell Tissue Res (2012) 349:97–104
Fujita Y, Endo S, Takai T, Yamashita T (2011) Myelin suppresses axon
regeneration by PIR-B/SHP-mediated inhibition of Trk activity.
EMBO J 30:1389–1401
Gao Y, Deng K, Hou J, Bryson JB, Barco A, Nikulina E, Spencer T,
Mellado W, Kandel ER, Filbin MT (2004) Activated CREB is
sufficient to overcome inhibitors in myelin and promote spinal
axon regeneration in vivo. Neuron 44:609–621
Gonzenbach RR, Schwab ME (2008) Disinhibition of neurite growth
to repair the injured adult CNS: focusing on Nogo. Cell Mol Life
Sci 65:161–176
Gonzenbach RR, Zoerner B, Schnell L, Weinmann O, Mir AK,
Schwab ME (2012) Delayed anti-Nogo-A antibody application
after spinal cord injury shows progressive loss of responsiveness.
J Neurotrauma 29:567-578
GrandPre T, Nakamura F, Vartanian T, Strittmatter SM (2000) Identi-
fication of the Nogo inhibitor of axon regeneration as a Reticulon
protein. Nature 403:439–444
He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R (2004) Reticulon
family members modulate BACE1 activity and amyloid-beta
peptide generation. Nat Med 10:959–965
Huber AB, Weinmann O, Brosamle C, Oertle T, Schwab ME (2002)
Patterns of Nogo mRNA and protein expression in the developing
and adult rat and after CNS lesions. J Neurosci 22:3553–3567
Ji B, Li M, Wu WT, Yick LW, Lee X, Shao Z, Wang J, So KF, McCoy
JM, Pepinsky RB, Mi S, Relton JK (2006) LINGO-1 antagonist
promotes functional recovery and axonal sprouting after spinal
cord injury. Mol Cell Neurosci 33:311–320
Jokic N, Gonzalez de Aguilar JL, Pradat PF, Dupuis L, Echaniz-Laguna
A, Muller A, Dubourg O, Seilhean D, Hauw JJ, Loeffler JP,
Meininger V (2005) Nogo expression in muscle correlates with
amyotrophic lateral sclerosis severity. Ann Neurol 57:553–556
Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg
MA, Schwab ME, Dupuis L, Loeffler JP (2006) The neurite
outgrowth inhibitor Nogo-A promotes denervation in an amyo-
trophic lateral sclerosis model. EMBO Rep 7:1162–1167
Joset A, Dodd DA, Halegoua S, Schwab ME (2010) Pincher-generated
Nogo-A endosomes mediate growth cone collapse and retrograde
signaling. J Cell Biol 188:271–285
Kilic E, ElAli A, Kilic U, Guo Z, Ugur M, Uslu U, Bassetti CL,
Schwab ME, Hermann DM (2010) Role of Nogo-A in neuronal
survival in the reperfused ischemic brain. J Cereb Blood Flow
Metab 30:969–984
Kim JE, Li S, GrandPre T, Qiu D, Strittmatter SM (2003) Axon
regeneration in young adult mice lacking Nogo-A/B. Neuron
38:187–199
Lee JK, Kim JE, Sivula M, Strittmatter SM (2004) Nogo receptor
antagonism promotes stroke recovery by enhancing axonal plas-
ticity. J Neurosci 24:6209–6217
Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, Yeh
HH, Shrager P, Giger RJ (2008) Synaptic function for the Nogo-66
receptor NgR1: regulation of dendritic spine morphology and
activity-dependent synaptic strength. J Neurosci 28:2753–2765
Lee JK, Geoffroy CG, Chan AF, Tolentino KE, Crawford MJ, Leal
MA, Kang B, Zheng B (2010) Assessing spinal axon regeneration
and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron
66:663–670
Li S, Strittmatter SM (2003) Delayed systemic Nogo-66 receptor
antagonist promotes recovery from spinal cord injury. J Neurosci
23:4219–4227
Liebscher T, Schnell L, Schnell D, Scholl J, Schneider R, Gullo M,
Fouad K, Mir A, Rausch M, Kindler D, Hamers FP, Schwab ME
(2005) Nogo-A antibody improves regeneration and locomotion
of spinal cord-injured rats. Ann Neurol 58:706–719
Lord-Fontaine S, Yang F, Diep Q, Dergham P, Munzer S, Tremblay P,
McKerracher L (2008) Local inhibition of Rho signaling by cell-
permeable recombinant protein BA-210 prevents secondary damage
and promotes functional recovery following acute spinal cord injury.
J Neurotrauma 25:1309–1322
McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005)
Experience-driven plasticity of visual cortex limited by myelin
and Nogo receptor. Science 309:2222–2226
Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N,
Perrin S, Sands B, Crowell T, Cate RL, McCoy JM, Pepinsky RB
(2004) LINGO-1 is a component of the Nogo-66 receptor/p75
signaling complex. Nat Neurosci 7:221–228
Mi YJ, Hou B, Liao QM, Ma Y, Luo Q, Dai YK, Ju G, Jin WL (2012)
Amino-Nogo-A antagonizes reactive oxygen species generation
and protects immature primary cortical neurons from oxidative
toxicity. Cell Death Differ (in press)
Montani L, Gerrits B, Gehrig P, Kempf A, Dimou L, Wollscheid B,
Schwab ME (2009) Neuronal Nogo-A modulates growth cone
motility via Rho-GTP/LIMK1/cofilin in the unlesioned adult nervous
system. J Biol Chem 284:10793–10807
Nakamura Y, Fujita Y, Ueno M, Takai T, Yamashita T (2011) Paired
immunoglobulin-like receptor B knockout does not enhance axonal
regeneration or locomotor recovery after spinal cord injury. J Biol
Chem 286:1876–1883
Nash M, Pribiag H, Fournier AE, Jacobson C (2009) Central nervous
system regeneration inhibitors and their intracellular substrates.
Mol Neurobiol 40:224–235
Niederost B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE (2002)
Nogo-A and myelin-associated glycoprotein mediate neurite
growth inhibition by antagonistic regulation of RhoA and Rac1.
J Neurosci 22:10368–10376
Oertle T, Klinger M, Stuermer CA, Schwab ME (2003a) A reticular
rhapsody: phylogenic evolution and nomenclature of the RTN/Nogo
gene family. FASEB J 17:1238–1247
Oertle T, Haar ME van der, Bandtlow CE, Robeva A, Burfeind P, Buss A,
HuberAB, SimonenM, Schnell L, Brosamle C, KaupmannK,Vallon
R, Schwab ME (2003b) Nogo-A inhibits neurite outgrowth and cell
spreading with three discrete regions. J Neurosci 23:5393–5406
Omoto S, Ueno M, Mochio S, Takai T, Yamashita T (2010) Genetic
deletion of paired immunoglobulin-like receptor B does not pro-
mote axonal plasticity or functional recovery after traumatic brain
injury. J Neurosci 30:13045–13052
Park KJ, Grosso CA, Aubert I, Kaplan DR, Miller FD (2010) p75NTR-
dependent, myelin-mediated axonal degeneration regulates neural
connectivity in the adult brain. Nat Neurosci 13:559–566
Peng X, Kim J, Zhou Z, Fink DJ, Mata M (2011) Neuronal Nogo-A
regulates glutamate receptor subunit expression in hippocampal
neurons. J Neurochem 119:1183–1193
Pernet V, Joly S, Dalkara D, Schwarz O, Christ F, Schaffer D, Flannery
JG, Schwab ME (2011) Neuronal Nogo-A upregulation does not
contribute to ER stress-associated apoptosis but participates in the
regenerative response in the axotomized adult retina. Cell Death
Differ (in press)
Pradat PF, Corse A, Shefner J, Rothstein JD, Leigh PN, Morrison KE,
et al (2011) A first-time-in-human study in ALS patients with the
anti-Nogo-A monoclonal antibody GSK1223249. Preliminary
results. In: 22nd international symposium on ALS/MND. Sydney,
Australia
Raiker SJ, Lee H, Baldwin KT, Duan Y, Shrager P, Giger RJ (2010)
Oligodendrocyte-myelin glycoprotein and Nogo negatively regulate
activity-dependent synaptic plasticity. J Neurosci 30:12432–12445
Raineteau O, Fouad K, Noth P, Thallmair M, Schwab ME (2001) Func-
tional switch between motor tracts in the presence of the mAb IN-1
in the adult rat. Proc Natl Acad Sci USA 98:6929–6934
Saxena S, Cabuy E, Caroni P (2009) A role for motoneuron subtype-
selective ER stress in disease manifestations of FALS mice. Nat
Neurosci 12:627–636
Schwab ME (2010) Functions of Nogo proteins and their receptors in
the nervous system. Nat Rev Neurosci 11:799–811
Cell Tissue Res (2012) 349:97–104 103
Shao Y, AkmentinW, Toledo-Aral JJ, Rosenbaum J, Valdez G, Cabot JB,
Hilbush BS, Halegoua S (2002) Pincher, a pinocytic chaperone for
nerve growth factor/TrkA signaling endosomes. J Cell Biol
157:679–691
Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire
N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V,
Pepinsky RB, Mi S (2005) TAJ/TROY, an orphan TNF receptor
family member, binds Nogo-66 receptor 1 and regulates axonal
regeneration. Neuron 45:353–359
Shi Q, Hu X, Prior M, Yan R (2009a) The occurrence of aging-dependent
reticulon 3 immunoreactive dystrophic neurites decreases cognitive
function. J Neurosci 29:5108–5115
Shi Q, Prior M, He W, Tang X, Hu X, Yan R (2009b) Reduced amyloid
deposition in mice overexpressing RTN3 is adversely affected by
preformed dystrophic neurites. J Neurosci 29:9163–9173
Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann
B, Christ F, Sansig G, Putten H van der, Schwab ME (2003)
Systemic deletion of the myelin-associated outgrowth inhibitor
Nogo-A improves regenerative and plastic responses after spinal
cord injury. Neuron 38:201–211
Spillmann AA, Bandtlow CE, Lottspeich F, Keller F, Schwab ME
(1998) Identification and characterization of a bovine neurite
growth inhibitor (bNI-220). J Biol Chem 273:19283–19293
Tagami S, Eguchi Y, Kinoshita M, Takeda M, Tsujimoto Y (2000) A
novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on
endoplasmic reticulum and reduces their anti-apoptotic activity.
Oncogene 19:5736–5746
Thallmair M, Metz GA, Z'Graggen WJ, Raineteau O, Kartje GL,
Schwab ME (1998) Neurite growth inhibitors restrict plasticity
and functional recovery following corticospinal tract lesions. Nat
Neurosci 1:124–131
Tsai SY, Papadopoulos CM, Schwab ME, Kartje GL (2011) Delayed
anti-Nogo-a therapy improves function after chronic stroke in
adult rats. Stroke 42:186–190
Voeltz GK, Prinz WA, Shibata Y, Rist JM, Rapoport TA (2006) A class
of membrane proteins shaping the tubular endoplasmic reticulum.
Cell 124:573–586
Wan Q, Kuang E, Dong W, Zhou S, Xu H, Qi Y, Liu Y (2007)
Reticulon 3 mediates Bcl-2 accumulation in mitochondria in
response to endoplasmic reticulum stress. Apoptosis 12:319–328
Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002a) P75
interacts with the Nogo receptor as a co-receptor for Nogo,
MAG and OMgp. Nature 420:74–78
Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM
(2002b) Localization of Nogo-A and Nogo-66 receptor proteins at
sites of axon-myelin and synaptic contact. J Neurosci 22:5505–5515
Wang X, Baughman KW, Basso DM, Strittmatter SM (2006) Delayed
Nogo receptor therapy improves recovery from spinal cord contu-
sion. Ann Neurol 60:540–549
WangX,Duffy P,McGeeAW,HasanO, GouldG, TuN, Harel NY,Huang
Y, Carson RE, Weinzimmer D, Ropchan J, Benowitz LI, Cafferty
WB, Strittmatter SM (2011) Recovery from chronic spinal cord
contusion after Nogo receptor intervention. Ann Neurol 70:805–821
Yang YS, Harel NY, Strittmatter SM (2009) Reticulon-4A (Nogo-A)
redistributes protein disulfide isomerase to protect mice from
SOD1-dependent amyotrophic lateral sclerosis. J Neurosci 29:13850–
13859
Yin Y, Cui Q, Li Y, Irwin N, Fischer D, Harvey AR, Benowitz LI (2003)
Macrophage-derived factors stimulate optic nerve regeneration. J
Neurosci 23:2284–2293
Zagrebelsky M, Schweigreiter R, Bandtlow CE, Schwab ME, Korte M
(2010) Nogo-A stabilizes the architecture of hippocampal neurons. J
Neurosci 30:13220–13234
Zheng B, Ho C, Li S, Keirstead H, Steward O, Tessier-Lavigne M
(2003) Lack of enhanced spinal regeneration in Nogo-deficient
mice. Neuron 38:213–224
Zorner B, Schwab ME (2010) Anti-Nogo on the go: from animal models
to a clinical trial. Ann N YAcad Sci 1198(Suppl 1):E22–E34
104 Cell Tissue Res (2012) 349:97–104
